三(羟基甲基)磷化氢 - CAS号 2767-80-8

物化性质

熔点：

48-56 °C(lit.)
沸点：

111-113 °C2.5 mm Hg(lit.)
密度：

1.137 (estimate)
闪点：

>230 °F
稳定性/保质期：

避免与不相容的材料、卤素和氧气接触。它会与卤素和氧气发生反应。

计算性质

辛醇/水分配系数(LogP)：

-1.8
重原子数：

7
可旋转键数：

3
环数：

0.0
sp3杂化的碳原子比例：

1.0
拓扑面积：

60.7
氢给体数：

3
氢受体数：

3

安全信息

危险品标志：

T
安全说明：

S26,S36/37/39,S45
危险类别码：

R25
WGK Germany：

3
海关编码：

2905199090
危险品运输编号：

UN 2811 6.1/PG 3
RTECS号：

PC3502500
储存条件：

密封保存，应储存在阴凉干燥的仓库中。

SDS

SDS：4497e9702ce962028afa8c1e9c6c5bd8

查看

Name:	Tris(hydroxymethyl)phosphine Material Safety Data Sheet
Synonym:
CAS:	2767-80-8

Section 1 - Chemical Product MSDS Name:Tris(hydroxymethyl)phosphine Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2767-80-8	Tris(hydroxymethyl)phosphine		220-445-6

Hazard Symbols: T
Risk Phrases: 25 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Toxic if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. Toxic if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid immediately. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2767-80-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: Insoluble.
Specific Gravity/Density:
Molecular Formula: C3H9O3P
Molecular Weight: 124.08

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, halogens, oxygen.
Hazardous Decomposition Products:
Carbon monoxide, oxides of phosphorus, carbon dioxide, formaldehyde.
Hazardous Polymerization: Will not occur.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2767-80-8: PC3502500 LD50/LC50:
CAS# 2767-80-8: Draize test, rabbit, eye: 100 uL/24H Severe; Draize test, rabbit, skin: 500 uL/24H Severe; Oral, rat: LD50 = 178 mg/kg.
Carcinogenicity:
Tris(hydroxymethyl)phosphine - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T
Risk Phrases:
R 25 Toxic if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 2767-80-8: No information available.
Canada
CAS# 2767-80-8 is listed on Canada's DSL List.
CAS# 2767-80-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2767-80-8 is listed on the TSCA inventory.

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

化学试剂

用途简介

暂无内容

用途

化学试剂

上下游信息

下游产品

中文名称英文名称 CAS号化学式分子量

三羟甲基氧化磷 tri(hydroxymethyl)phosphine oxide 1067-12-5 C₃H₉O₄P 140.076

中文名称	英文名称	CAS号	化学式	分子量
三羟甲基氧化磷	tri(hydroxymethyl)phosphine oxide	1067-12-5	C₃H₉O₄P	140.076

反应信息

作为反应物：

描述：

三(羟基甲基)磷化氢在 air 作用下，以乙醇为溶剂，反应 16.0h，生成三羟甲基氧化磷

参考文献：

名称：

白磷的光催化亚硝化

摘要：

有机磷化合物 (OPC) 是非常重要的化学品，在学术界和工业界都有大量应用。在此，我们描述了一种使用廉价、市售的二锡烷 (Bu 3 Sn) 2和蒽醌作为简单光催化剂的白磷 (P 4 ) 的锡酸化的简单光催化方法。随后对所得的单烷基化单膦中间体 (Bu 3 Sn) 3 P进行“一锅”转化，可直接、方便且通用地获得有价值的 OPC，例如酰化膦和四烷基鏻盐。

DOI：

10.1039/d2cc03474c
作为产物：

描述：

四羟甲基氯化磷在 sodium hydroxide 作用下，以水为溶剂，反应 1.0h，生成三(羟基甲基)磷化氢

参考文献：

名称：

具有水溶性CAP配体作为体外抗癌剂的新型半三明治钌（II）芳烃配合物

摘要：

获得了1,4,7-三氮杂-9-磷三环[5.3.2.1]十三烷（CAP）的钌（II）芳烃配合物。针对癌细胞系的细胞毒性研究显示，其活性高于相应的PTA类似物，并且与对非癌细胞的作用相比，该复合物具有合理程度的癌细胞选择性。

DOI：

10.1021/acs.inorgchem.7b00915
作为试剂：

描述：

三乙氧基硅烷、 cyclohexadec-7-yn-1-ol 在 tris(acetonitrile)pentamethylcyclopentadienylruthenium(II) hexafluorophosphate 、三(羟基甲基)磷化氢、 silver fluoride 作用下，以二氯甲烷、四氢呋喃、甲醇、水为溶剂，反应 3.75h，以74%的产率得到(7E)-cyclohexadec-7-en-1-one

参考文献：

名称：

通过具有选择性氢化的闭环炔复分解合成，以及 (7E)- 和 (7Z)-Cyclohexadec-7-enone (Aurelione®) 的嗅觉比较

摘要：

环十六-7-烯酮（6，Aurelione®）的两种CC-键异构体都是通过环十六-7-炔醇（16）通过icosa-2,18-diyn-9-ol的闭环炔复分解选择性合成的（ 15)，采用由 Mo(CO)6 和 4-(三氟甲基)苯酚原位形成的催化剂。氯铬酸吡啶 (PCC) 氧化和随后的 Lindlar 氢化得到 (7Z) 构型的异构体 (7Z)-6，而中间体环十六烷-7-炔酮 (17) 的氢化硅烷化，然后脱甲硅烷基化，提供 (7E) 构型的环十六烷‐7-烯酮 ((7E)‐6)。炔复分解反应的底物由环庚酮 (7) 通过氯甲基卡宾环加成到其三甲基甲硅烷基烯醇醚 8 上制备，随后加合物 9 在重排为 2-甲基环辛基-2-烯酮 (10) 下环扩大，其经过 WeitzScheffer 环氧化和 Eschenmoser Ohloff 裂解成非 7-ynal (12)。它与 11-bromoundec-2-yne

DOI：

10.1002/cbdv.201400011

点击查看最新优质反应信息

文献信息

Photoactivated in Vitro Anticancer Activity of Rhenium(I) Tricarbonyl Complexes Bearing Water-Soluble Phosphines

作者：Sierra C. Marker、Samantha N. MacMillan、Warren R. Zipfel、Zhi Li、Peter C. Ford、Justin J. Wilson

DOI：10.1021/acs.inorgchem.7b02747

日期：2018.2.5

evaluated as photoactivated anticancer agents in human cervical (HeLa), ovarian (A2780), and cisplatin-resistant ovarian (A2780CP70) cancer cell lines. All of the complexes bearing THP and DAPTA exhibited a cytotoxic response upon irradiation with minimal toxicity in the absence of light. Notably, the complex with DAPTA and 1,10-phenanthroline gave rise to an IC50 value of 6 μM in HeLa cells upon irradiation

十五种通式为[Re（CO）3（NN）（PR 3）] +的水溶性rh化合物，其中NN为二亚胺配体，PR 3为1,3,5-三氮杂-7-磷金刚烷（PTA），三（羟甲基）膦（THP）或1,4-二乙酰基-1,3,7-三氮杂-5-磷酸环己二酸酯[3.3.1]壬烷（DAPTA）的合成，并通过多核NMR光谱，IR光谱进行了表征，和X射线晶体学。带有THP和DAPTA配体的配合物在空气平衡的水溶液中显示出基于三重态的发光，量子产率为3.4％至11.5％。此外，THP和DAPTA配合物在365 nm光线照射下会发生CO配体的光解，其量子产率为1.1％至5.5％，并敏化了1 O 2的量子产率高达70％。相反，所有带有PTA配体的配合物都是非发光的，并且在365 nm的光照射下不会发生光解。这些化合物被评估为人类宫颈癌（HeLa），卵巢癌（A2780）和顺铂耐药卵巢癌（A2780CP70）癌细胞系中的光活化抗癌
[EN] RHENIUM COMPLEXES AND METHODS OF USE FOR TREATING CANCER<br/>[FR] COMPLEXES DE RHÉNIUM ET MÉTHODES D'UTILISATION POUR LE TRAITEMENT DU CANCER

申请人：UNIV CORNELL

公开号：WO2017223428A1

公开（公告）日：2017-12-28

A composition comprising the following structure: (formula I) wherein Re represents a rhenium ion having a +1 charge; (formula II) represents an uncharged bidentate bicyclic ligand bonded to the rhenium (Re) by two ring nitrogen (N) atoms; and L is a neutral ligand independently selected from CO and neutral phosphine molecules, wherein at least one of the L groups is a CO molecule; and X- represents a non-coordinating monovalent anion; wherein (formula II) is unsubstituted or substituted on any of its two rings, and said neutral phosphine molecule may or may not contain a phosphorus atom as a ring phosphorus atom; provided that, if (formula II) is unsubstituted, then one or two of said L groups are selected from said neutral phosphine molecules, with the provision that at least one of the neutral phosphine molecules has a phosphorus atom as a ring phosphorus atom. Methods for treating cancer by administering the above complex are also disclosed.

以下结构的组成物：(公式I)，其中Re代表一个带有+1电荷的铼离子；(公式II)代表一个未带电的双齿双环配体，通过两个环上的氮(N)原子与铼(Re)结合；L是独立选择的电中性配体，选自CO和电中性磷化氢分子，其中至少一个L基团是CO分子；X-代表一个非配位的单价阴离子；(公式II)未取代或在其任一双环上进行取代，并且所说的电中性磷化氢分子可能含有也可能不含有作为环磷原子的磷原子；条件是，如果(公式II)未取代，则所说的L基团中有一个或两个选自所说的电中性磷化氢分子，并且至少有一个电中性磷化氢分子具有作为环磷原子的磷原子。还公开了通过施用上述复合物来治疗癌症的方法。
Optimizing ligand structure for low-loading and fast catalysis for alkynyl-alcohol and -amine cyclization

作者：James M. Stubbs、Benjamin J. Bridge、Johanna M. Blacquiere

DOI：10.1039/c9dt01870k

日期：——

The catalytic performance was evaluated for a series of [Ru(Cp/Cp*)(P^R₂N^R′₂)(MeCN)]PF₆ complexes, in which the steric and electronic properties of the primary coordination sphere were varied (R = Ph, t-Bu, Bn; and Cp vs. Cp*).

对于一系列的[Ru(Cp/Cp*)(P^R₂N^R′₂)(MeCN)]PF₆配合物进行了催化性能评估，其中初级配位球体的立体和电子特性发生了变化（R = Ph, t-Bu, Bn; 以及Cp vs. Cp*）。
Enhanced Reductive Elimination of Dialkylgold(III) Complexes in Water

作者：Nobuyuki Komine、Kaoru Ichikawa、Anna Mori、Masafumi Hirano、Sanshiro Komiya

DOI：10.1246/cl.2005.1704

日期：2005.12

Neutral and cationic dimethyl- or diethylgold(III) complexes having a water-soluble phosphine ligand, AuR2XL and [AuR2L2]X (R = Me or Et; X = Br or I; L = TPPTS, TPPMS, THMP, or DHMPE), are prepared. Reductive elimination involving C–C bond formation at Au(III) in water is faster than those in organic solvents.

制备了含有水溶性膦配体的中性及阳离子二甲基或二乙基金(III)配合物AuR₂₂L₂]X（R=Me或Et；X=Br或I；L=TPPTS、TPPMS、THMP或DHMPE）。在水溶液中，金(III)位点上的C-C键形成涉及的还原消除反应比在有机溶剂中更快。
[EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'HÉPATITE C

申请人：BOEHRINGER INGELHEIM INT

公开号：WO2011063502A1

公开（公告）日：2011-06-03

Compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, maintain good activity against NS3 proteases containing clinically relevant genotype 1 a R155K and genotype 1 b D168V resistance mutations. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

式（I）中的化合物，其中R1、R2、R3、R4和R5如本文所定义，对含有临床相关的基因型1a R155K和基因型1b D168V耐药突变的NS3蛋白酶保持良好的活性。这些化合物可用作HCV NS3蛋白酶的抑制剂，用于治疗丙型肝炎病毒感染。

三(羟基甲基)磷化氢 | 2767-80-8

物质功能分类

分子结构分类

物化性质

计算性质

安全信息

SDS

制备方法与用途

上下游信息

反应信息

文献信息

同类化合物

相关功能分类

相关结构分类

热门分子